Unique ID issued by UMIN | UMIN000008610 |
---|---|
Receipt number | R000010119 |
Scientific Title | To clarify different effects of daily and weekly hPTH(1-34), teriparatide, administration on local and systemic bone metabolism during healing period after vertebral fracture. |
Date of disclosure of the study information | 2012/08/06 |
Last modified on | 2017/10/23 17:12:51 |
To clarify different effects of daily and weekly hPTH(1-34), teriparatide, administration on local and systemic bone metabolism during healing period after vertebral fracture.
To test different effects of daily and weekly teriparatide on local and systemic bone metabolism during fracture healing after vertebral fracture
To clarify different effects of daily and weekly hPTH(1-34), teriparatide, administration on local and systemic bone metabolism during healing period after vertebral fracture.
To test different effects of daily and weekly teriparatide on local and systemic bone metabolism during fracture healing after vertebral fracture
Japan |
osteoporosis
Orthopedics |
Others
NO
To clarify different effects of daily and weekly hPTH(1-34), teriparatide, administration during healing period after vertebral fracture on the fracture site, pain and systemic bone turnover, and different indication of those two agents.
Safety,Efficacy
Confirmatory
Pragmatic
Bone metabolic markers
Vertebral and femoral bone mineral density, numbers of new vertebral fractures during the study period, VAS, JOQOL, RDQ, QUEST, and bony union
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
YES
NO
Central registration
2
Treatment
Medicine |
Teriparatide Acetate
Teriparatide (Genetical Recombination)
60 | years-old | <= |
Not applicable |
Female
Post-menopausal women of 60-y-o or above with sever osteoporosis who have a fresh vertebral fracture and understand, and literary approve to be included to this study.
#1; The fresh vertebral fracture, what occur during 2 weeks, is defined with history, physical examination and X-ray appearances and/or MRI of spine.
#2; The sever osteoporosis is diagnosed to a patient whose point is accounting for 3 or above by our appraisal standard as follow.
Point
70%YAM>BMD=/>65% 1
65%YAM>BMD=/>60% 2
60%YAM>BMD 3
New vertebral fracture 1
Using corticosteroid 1
Old vertebral fracture =1 1
Old vertebral fractures >1 2
Sever osteoporosis: total 3=/<
1. Patients in whom study drugs (teriparatide) are contraindicated
2. Serious renal, hepatic, or cardiac disease
3. Secondly osteoporosis
4. Patients who are considered inappropriate for enrollment by the investigator for any other reason
40
1st name | |
Middle name | |
Last name | Shinya Tanaka |
Saitama Medical University
Department of Orthopaedic Surgery
Morohongo 38, moroyamacho, Irumagun, Saitamaken, Japan
049-276-1238
tnk_sny@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Shinya Tanaka |
Saitama Medical University
Department of Orthopaedic Surgery
350-0495, Morohongo 38, Moroyama-cho, Iruma-gun, Saitama, Japan
049-276-1238
tnk_sny@saitama-med.ac.jp
Saitama Medical University
Japan Osteoporosis Foundation
Non profit foundation
Japan
NO
埼玉医科大学病院(埼玉県)、埼玉医科大学かわごえクリニック(埼玉県)、小川日本赤十字病院(埼玉県)、関越病院(埼玉県)、若葉病院(埼玉県)
2012 | Year | 08 | Month | 06 | Day |
Unpublished
Completed
2012 | Year | 06 | Month | 28 | Day |
2012 | Year | 08 | Month | 06 | Day |
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 07 | Month | 31 | Day |
2014 | Year | 07 | Month | 31 | Day |
2015 | Year | 03 | Month | 31 | Day |
2012 | Year | 08 | Month | 03 | Day |
2017 | Year | 10 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010119